Abstract
Background: Assessment of bronchodilator response is a common practice in respiratory function laboratories. The most commonly used drugs are Salbutamol-S and Ipratropium Bromide-BI.
Aims: Characterize the response to bronchodilators according to gender and disease, age and disease; evaluate the variation of FVC and FEV1 according to the drug used according to gender and age; determine the coefficients of agreement between responses to bronchodilators.
Methods: 141 subjects (43 asthmatics; 98 COPD) underwent 2 PFT’s with a 1 week interval with a different drug. The sample was studied according to gender and age group taking into account the underlying pathology.
Results: In women it was the BI that allowed to characterize as responders in asthma (43.5%) and in COPD (55.0%). In men, it was the S that classified as responders with asthma (43.8%) and COPD (52.4%). No differences were found regarding the variation of FVC and FEV1 (p> 0.05) in both genders regardless of pathology. The analysis of the agreement coefficients was significant in both genders in COPD (0.340 and 0.319). In asthmatics ≤60 years old, the S identified as responders a greater number of individuals (50%) and> 60 years old, both drugs had the same capacity (28.6%). In COPD in individual’s ≤60 years old the BI classified the highest number of responders (60.0%) and> 60 years old was the S (47.2%). Regarding the agreement coefficients, they were significant in both age groups only in COPD (0.416 and 0.273).
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA1849.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021